

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Shire Human Genetic Therapies, Inc.	04/05/2013
RECEIVING PARTY DATA	
Name:	Synageva BioPharma Corp.
Street Address:	128 Spring Street
Internal Address:	Suite 520
City:	Lexington
State/Country:	MASSACHUSETTS
Postal Code:	02421
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13967050
CORRESPONDENCE DATA	
Fax Number:	6175025002
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	617-248-5000
Email:	patentdocket@choate.com
Correspondent Name:	Choate, Hall & Stewart LLP
Address Line 1:	Two International Place
Address Line 4:	Boston, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2011080-0008
NAME OF SUBMITTER:	Fangli Chen, PhD, JD
Signature:	/Fangli Chen/
Date:	08/14/2013

OP \$40.00 13967050

Total Attachments: 6

source=Assignment_Shire_to_Synageva#page1.tif

source=Assignment_Shire_to_Synageva#page2.tif

source=Assignment_Shire_to_Synageva#page3.tif

source=Assignment_Shire_to_Synageva#page4.tif

source=Assignment_Shire_to_Synageva#page5.tif

source=Assignment_Shire_to_Synageva#page6.tif

ASSIGNMENT

THIS ASSIGNMENT AGREEMENT (“Assignment”), dated April 5, 2013, is made and entered into by and between **Shire Human Genetic Therapies, Inc.**, a Delaware corporation having a usual place of business at **300 Shire Way, Lexington, Massachusetts 02421** (hereinafter “**Assignor**”), and **Synageva BioPharma Corp.**, a Delaware corporation having a usual place of business at **128 Spring Street, Suite 520, Lexington, Massachusetts 02421** (hereinafter “**Assignee**”).

WHEREAS, Assignor owns all right, title and interest in and to the patent applications identified in **Exhibit A (“Family 2 Applications”)**;

WHEREAS, Assignor owns a joint, undivided interest with Children’s Hospital Medical Center d/b/a Cincinnati Children’s Hospital Medical Center (“**CHMC**”) in and to the patent applications identified in **Exhibit B (“Family 3 Applications”)**;

WHEREAS, Assignee desires to acquire all of Assignor’s rights, title, and interests interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, including the Settlement Agreement among Assignor, Shire AG, Children’s Hospital Research Foundation, a division of CHMC, Assignee and Synageva BioPharma Limited, executed on April 5, 2013, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee, its successors, assigns, and legal representatives, its entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to: (i) the Family 2 Applications and Family 3 Applications; (ii) any and all inventions described therein; (iii) any priority applications thereto; (iv) all rights of priority with respect thereto; and (v) any divisionals, continuations, continuations-in-part or other applications sharing common priority with any of the foregoing anywhere in the world (and all resulting patents therefrom, any reexaminations, reissues, renewals, restorations, and extensions (including patent term adjustments, patent term extensions, supplemental protection certificates or the equivalent thereof) of any of such patents or patent applications, and any foreign counterparts of any of the foregoing (whether or not listed on **Exhibit A** or **Exhibit B**) (collectively the “**Assigned Patent Rights**”); such Assigned Patent Rights to be held and enjoyed by Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which any such patents may be granted as fully and entirely as the same would have been held by Assignor had this Assignment not been made, Assignor hereby conveys all choses in action pertaining to the Assigned Patent Rights including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the Assigned Patent Rights. Assignor hereby confirms that Assignor’s sale, assignment and transfer is effective as of the date first written above.

AND, Assignor hereby acknowledges that this Assignment, being of its entire right, title, and interest in and to the inventions described in the Family 2 Applications, carries with it the right in Assignee, by attorneys and agents of Assignee's selection, to apply for and receive any and all patent(s) for said inventions in its own name as assignee of the entire right, title and interest therein;

AND, Assignor hereby acknowledges that this Assignment, being of its entire right, title, and interest in and to the inventions described in the Family 3 Applications, carries with it, as between Assignor and Assignee, the right in Assignee, by attorneys and agents of Assignee's selection, to apply for and receive any and all patent(s) for said inventions in accordance with Section 4.1 (Patent Prosecution and Maintenance of Family 3 Patents) and Section 4.2 (CHMC's Election to Prosecute Family 3 Patents) of that certain Exclusive Sublicense Agreement dated as of the date of this Assignment by and between Shire AG and Assignee;

AND, Assignor hereby further agrees for itself and its executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts that may be reasonably necessary to secure fully the Assigned Patent Rights and patents to Assignee, its successors, assignees, and legal representatives, but at Assignee's expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation or continuation-in-part applications, the execution of all rightful declarations, oaths, assignments and other papers, and generally by doing other things reasonably possible to aid Assignee in securing and maintaining proper patent protection for the inventions and for vesting title in the Assigned Patent Rights and other rights conveyed herewith;

AND, Assignor hereby requests the Director of Patents and Trademarks of the United States to issue any and all patent(s) as shall be granted upon the Assigned Patent Rights or other rights conveyed herewith to Assignee, its successors, assigns, and legal representatives.

[Signature page follows.]

IN WITNESS WHEREOF, each of the parties has caused this Assignment to be duly executed and delivered as of the date first written above by its duly authorized representative.

SHIRE HUMAN GENETIC THERAPIES, INC.

By: *[Signature]*

Name: JONATHAN POOLE

Title: SVP FINANCE

Commonwealth of Massachusetts

County of Middlesex


Before me this 5th day of April, 2013, personally appeared Jonathan Poole, and proved to me through satisfactory evidence of identity, which was known to me, to be the person whose name is signed on the preceding or attached document, and acknowledged that he/she executed the same, of his/her own free will and for the purposes set forth

NOTARY PUBLIC

[Signature]

Name: Bianka Kolb

My Commission Expires: Jan - 28, 2016



[Signature Page to the Assignment]

SYNAGEVA BIOPHARMA CORP.

By: [Signature]


Name: Stephen Mahoney

Title: General Counsel

Commonwealth of Massachusetts

County of Middlesex

Before me this 5 day of April, 2013, personally appeared Stephen Mahoney, and proved to me through satisfactory evidence of identity, which was MA Drivers License, to be the person whose name is signed on the preceding or attached document, and acknowledged that he/she executed the same, of his/her own free will and for the purposes set forth



NOTARY PUBLIC

[Signature]
Name: _____

My Commission Expires: February 13, 2020

[Signature Page to the Assignment]

EXHIBIT A
FAMILY 2 APPLICATIONS

Family 2 Patents				
Serial No	Patent Title	Country	File Date	Status
PCT/US2012/025239	Methods for Treating Lysosomal Acid Lipase Deficiency	PCT	2/15/2012	Pending
61/443,179	Methods for Treating Lysosomal Acid Lipase Deficiency	US	2/15/2011	Expired

EXHIBIT B
FAMILY 3 APPLICATIONS

Family 3 Patents							
Patent No	Serial No	Patent Title	Country	File Date	Issue Date	Status	Tech ID
	PCT/US2012/025233	Methods for Treating Lysosomal Acid Lipase Deficiency	PCT	2/15/2012		Pending	2011-0202
	61/443,079	Methods for Treating Lysosomal Acid Lipase Deficiency	US	2/16/2011		Pending	2011-0202